Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market To Be At Forefront By 2026

Acute Bacterial Skin and Skin Structure Infections
(ABSSSI) Market To Grow Like Never Before By
2026
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Active
Ingredients (Delafloxacin, Vancomycin, Ceftaroline fosamil, Oritavancin,
Tedizolid, Daptomycin, Tigecycline, Linezolid and Others), By Route of
Administration (Oral, Parenteral, and Tropical), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By
Geography - Global Industry Insights, Trends, Outlook and Opportunity Analysis
2018-2026
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue
infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as
lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a
minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus
(MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus,
Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI.
This infection is difficult for treatment due to increasing prevalence of drug resistant strains, especially
in Staphylococcus spp. and Enterococcus spp. ABSSSI market is expected to exhibit growth at a
trajectory rate, owing to increasing number of patients suffering from these and large number of
pipeline products, expected to receive approved in the forecast period. Click To Read More On Acute
Bacterial Skin and Skin Structure Infections (ABSSSI) Market.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Driver
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
market is increasing research and development activities by pharmaceutical and biopharmaceutical
companies to develop new products and novel treatment. For instance, in 2017, Cempra announced
promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year,
Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI
medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi
received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial
drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by
susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes,
Streptococcus agalactlae etc.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1531
Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will
further propel growth of the ABSSSI market. For instance, according to article published in 2015 of
PLoS One journal, skin and skin structure infections related hospital admissions were 1.6% in 2005,
increased to 2.0% in 2011.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Competitor
Key players in the global acute bacterial skin and skin structure infections (ABSSSI) market are
Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord
Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Fresenius SE & Co. KGaA, Sandoz Inc. (a
subsidiary of Novartis), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva
Pharmaceutical Industries Ltd. The ABSSSI market players are involved in strategic planning for
expanding the market share of the company. For instance, in 2014, Merck & Co., Inc. acquired Cubist
Pharmaceuticals for US$ 9.5 billion.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Regional Analysis
Globally, acute bacterial skin and skin structure infections (ABSSSI) market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominate
position in ABSSSI market, and this is attributed to large number of pipeline products by the regional
market players. However, Asia Pacific is expected to witness fast growth, owing to increasing
awareness of ABSSSI treatment and manufacturers’ geographical expansion. For instance, Basilea
Pharmaceutics Ltd. signed an agreement with Shenzhen China Resources Gosun Pharmaceutical Co.,
in year 2017, to treat Methicillin resistant Staphylococcus aureus infection in China, Hong Kong and
Macao by Basilea’s Zevtera.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2.

Download Report